French pharmaceutical company Les Laboratoires Servier has purchased a licence option to develop and commercialise MacroGenics’ MGA271, an immune-stimulating antibody for the potential treatment of solid tumours, in a deal potentially worth up to US$450 M. The antibody, which has been optimised using MacroGenics’ proprietary Fc optimisation platform, is currently being tested in a Phase I study for patients with refractory B7-H3-expressing neoplasms.